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Abstract: Pancreatic cancer develops and progresses through complex, cumulative 
biological processes involving metabolic disorder, local inflammation, and deregulated 
molecular pathways. The resulting tumor aggressiveness hampers surgical intervention and 
renders pancreatic cancer resistant to standard chemotherapy and radiation therapy. Based 
on these pathologic properties, several therapeutic strategies are being developed to reverse 
refractory pancreatic cancer. Here, we outline molecular targeting therapies, which are 
primarily directed against growth factor receptor-type tyrosine kinases deregulated in 
tumors, but have failed to improve the survival of pancreatic cancer patients. Glycogen 
synthase kinase-3β (GSK3β) is a member of a serine/threonine protein kinase family that 
plays a critical role in various cellular pathways. GSK3β has also emerged as a mediator of 
pathological states, including glucose intolerance, inflammation, and various cancers  
(e.g., pancreatic cancer). We review recent studies that demonstrate the anti-tumor effects 
of GSK3β inhibition alone or in combination with chemotherapy and radiation. GSK3β 
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inhibition may exert indirect anti-tumor actions in pancreatic cancer by modulating 
metabolic disorder and inflammation. 
Keywords: pancreatic cancer; glucose intolerance; inflammation; oncogenic pathways; 
therapeutic target; GSK3β 
 
Abbreviations 
AMPK, 5′-AMP-activated protein kinase; ATP, adenosine triphosphate; CDK, cyclin-dependent 
kinase; COX-2, cyclooxygenase-2; CT, computed tomography; DCA, dichloroacetate; 2-DG, 2-deoxy-
D-glucose; DM, diabetes mellitus; DPC, deleted in pancreatic carcinoma; EGF, epidermal growth 
factor; EGFR, EGF receptor; EMT, epithelial-mesenchymal transition; FDG, [
18
F] fluoro-2-D-
deoxyglucose; FGF, fibroblast growth factor; GSK3β, glycogen synthase kinase-3β; HGF, hepatocyte 
growth factor; hTERT, human telomerase reverse transcriptase; IGF-1, insulin-like growth factor-1; 
LKB1, liver kinase B1; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; 
NADPH, nicotinamide adenine dinucleotide phosphate; NF-κB, nuclear factor-κB; NO, nitric oxide;  
iNOS, inducible NO synthase; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor;  
PDH, pyruvate dehydrogenase; PDK1, PDH kinase 1; PET, positron emission tomography;  
PI3K, phosphatidylinositol 3′-kinase; PPARγ, peroxisome proliferator-activated receptor-γ; PSC, 
pancreatic stellate cell; ROS, reactive oxygen species; TCA, tricarboxylic acid; TGF, transforming 
growth factor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 
1. Introduction 
Pancreatic cancer is a devastating disease and a major unresolved health problem due to its late 
clinical diagnosis and predisposition towards metastasis [1,2]. Pancreatic cancer is characterized by 
highly proliferative and invasive tumor cells [3]. Despite progress in approaches to treatment [4], such 
aggressive biological behavior thwarts early diagnosis and curative surgical intervention and renders 
tumors resistant to conventional chemotherapy, radiation therapy, and their combination [5-7], leading 
to a poor prognosis [8]. Therefore, understanding the detailed molecular and biological basis of pancreatic 
cancer pathogenesis facilitates advances in the diagnosis, treatment, and prevention of this disease. 
Pancreatic cancer develops through a series of complex, cumulative biological processes involving 
metabolic disorder and chronic local inflammation in association with stromal changes and deregulated 
molecular pathways (Figure 1). Based on these pathologic properties, new therapeutic strategies are 
being developed to reverse the refractory stage of pancreatic cancer. Here, we review the 
multidimensional processes leading to pancreatic cancer development and progression, and discuss 
biology-based therapeutic alternatives to conventional cancer treatments. In addition, we highlight an 
emerging strategy for cancer treatment that targets glycogen synthase kinase 3β (GSK3β), focusing on 
the effect of its deregulation on pancreatic cancer. 
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Figure 1. Molecular and biological pathways involved in the development and progression 
of pancreatic cancer and putative mechanisms underlying the anticancer effects of 
metformin, 2-deoxyglucose (2-DG), and dichloroacetate (DCA). The gray triangle in a box 
indicates a molecular target. Abbreviations: EMT, epithelial-to-mesenchymal transition; 
PSCs, pancreatic stellate cells; Warburg, Warburg effect. 
 
2. Metabolic Disorder Coincides with Pancreatic Cancer 
Although systemic metabolic disorders such as obesity and type II diabetes mellitus (DM) influence 
the risk of developing pancreatic cancer and clinical outcomes (reviewed in [9,10]), the abnormal 
metabolic profile of cancer cells dictates their survival, proliferation, and invasion, as well as 
susceptibility to chemotherapy and radiation [11,12]. Thus, metabolic disorder and altered tumor cell 
metabolism are potential targets for cancer treatment and (chemo) prevention [13,14].  
2.1. Obesity, Glucose Intolerance, and Pancreatic Cancer 
The association between obesity/DM and pancreatic cancer risk has long been controversial. 
However, recent reviews and meta-analyses of prospective observational studies have demonstrated 
that obesity, defined by an increased body mass index, is significantly associated with a risk of 
pancreatic cancer development [15,16]. DM is also a clinical manifestation of pancreatic cancer, and 
case-control and prospective studies have demonstrated an increased risk of pancreatic cancer in 
patients with long-term DM [17-19]. Obesity is associated with the early manifestations of pancreatic 
cancer and lower overall patient survival [20], although the influence of DM on pancreatic cancer 
progression or morbidity is not clear [10]. Possible mechanisms behind the association between 
obesity and worse clinical outcomes may include increased risk of DM, thrombosis, or other 
comorbidities; impaired immune response leading to aggressive tumor behavior; and poor response to 
conventional anticancer therapies [10]. The effect of obesity and DM on the development and 
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progression of pancreatic cancer appears to be mediated by adipokines, reactive oxygen species (ROS), 
inflammatory cytokines, and insulin resistance, which result in activation of insulin-like growth  
factor-1 (IGF-1) and mammalian target of rapamycin (mTOR) pathways (reviewed in [10]). 
A number of studies have reported the potential role of glucose-lowering therapies in reducing the 
risk of pancreatic cancer (reviewed in [21]). Metformin is a biguanide that is most frequently 
prescribed for diabetes [22]. Recently, a comprehensive review and meta-analysis of epidemiologic 
studies demonstrated an inverse correlation between the use of metformin and incidence of pancreatic 
cancer and overall survival of patients with diabetes [23]. Increasing evidence also suggests that 
metformin exerts a therapeutic effect against cancer [24,25]. Metformin decreases insulin resistance 
and indirectly reduces levels of insulin and IGF-1, which promote cancer cell proliferation [26]. 
Further, metformin activates the tumor suppressor pathway mediated by liver kinase B1 (LKB1) and  
5′ AMP-activated protein kinase (AMPK), an important sensor of cellular energy status [27], thereby 
inactivating mTOR signaling [14]. IGF-1 receptor and G protein-coupled receptor signaling is 
implicated in the autocrine-paracrine stimulation of a variety of malignant tumors, including exocrine 
pancreatic cancer. Recent studies demonstrated that metformin-induced activation of AMPK disrupts 
the crosstalk between insulin/IGF-1 receptor and G protein-coupled receptor signaling pathways in 
pancreatic cancer cells and inhibits proliferation of these cells in xenograft models, suggesting this 
crosstalk as a target for treatment of pancreatic cancer by metformin [28].  
2.2. Distinct Metabolic Properties of Cancer Cells 
The fundamental metabolic characteristics of cancer cells include increased glucose uptake, aerobic 
glycolysis even under normoxic condition (Warburg effect) [29], and impaired oxidative phosphorylation 
in the tricarboxylic acid (TCA) cycle, which results in mitochondrial uncoupling [30]. These properties 
could explain the ability of cancer cells to survive, invade host tissues, and resist the induction of apoptosis 
by chemotherapeutic agents and ionizing radiation [30,31]. However, the glycolytic phenotype of cancer 
cells is a potential target for cancer diagnosis and treatment [32]. For example, enhanced glucose uptake by 
cancer cells can be used to visualize cancer by positron emission tomography (PET) using the radioisotope-
labeled glucose analogue 2-[
18
F]-fluoro-2-deoxy-D-glucose (FDG). FDG-PET in combination with 
computed tomography (PET-CT) enables detection of metastatic lesions of most cancers with both 
sensitivity and specificity greater than 90% [33]. Pharmacologic agents targeting the glycolytic phenotype 
of cancer cells include 2-deoxy-D-glucose (2-DG) and dichloroacetate (DCA). 
A glucose analogue, 2-DG, is the most attractive agent for targeting aberrant glucose metabolism in 
cancer cells [34]. 2-DG inhibits glucose transport by competing with glucose transporters and is 
subsequently phosphorylated by hexokinase to form 2-DG-6-phospate. Phosphorylated 2-DG is not 
further metabolized by inhibiting glucose-6-phosphate isomerase, thereby reducing the production of 
adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide phosphate (NADPH) from 
glycolysis coupled with the pentose phosphate pathway. Thus, 2-DG exerts antitumor effects by 
starving cancer cells [34]. 
The association between the glycolytic phenotype (i.e., TCA cycle defects) and resistance to 
apoptosis is attributed to decreased mitochondrial hydrogen peroxide production and cytochrome C 
release [30,31]. Pyruvate dehydrogenase (PDH) plays a crucial role in triggering the TCA cycle by 
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converting pyruvate to citric acid. PDH kinase 1 (PDK1), which phosphorylates and inactivates PDH, 
is frequently overactivated in cancer cells, resulting in an impaired TCA cycle and mitochondrial 
hyperpolarization. Thus, inhibiting PDK1 would re-activate PDH and restore mitochondrial membrane 
polarity, thereby facilitating cancer cell apoptosis in response to chemotherapeutic agents and radiation. 
DCA, an orally bio-available small molecule, is a well characterized PDK1 inhibitor. The ability of 
DCA to inhibit lactate production (by stimulating PDH and the TCA cycle) has been long used to treat 
lactic acidosis, which complicates inherited mitochondrial disorders [35,36]. A recent study 
demonstrated that DCA induces cancer cell apoptosis by selectively inhibiting PDK1 in cancer cells, 
leading to metabolic remodeling from glycolysis to glucose oxidation and normalization of 
mitochondrial function [37]. A recent clinical trial of oral DCA in children with congenital lactic 
acidosis reported that DCA was well tolerated and safe [36]. Thus, orally available DCA is a 
promising selective anticancer agent.  
3. Inflammation and Stromal Reactions in Pancreatic Cancer 
The well recognized link between chronic inflammation and tumor development in many 
organs [38] is consistent with the reported causative association and interaction between chronic 
pancreatitis and pancreatic cancer [39-41]. In addition to the etiologic role of inflammation in 
carcinogenesis, systemic and local inflammation are frequent manifestations of pancreatic cancer and 
have been implicated in tumor progression and clinical outcomes [39]. 
3.1. Chronic Pancreatitis and Pancreatic Cancer 
Chronic pancreatitis is a risk factor for developing pancreatic cancer [39-41]. This association is 
supported by a recent meta-analysis of 22 well-performed epidemiologic studies [42]. The risk of 
developing pancreatic cancer for patients with hereditary pancreatitis is much higher than for patients 
with sporadic chronic pancreatitis [43-45]. The incidence of chronic pancreatitis in the general 
population is only about 5 to 10 per 100,000 persons a year, as estimated from hospitalization data. In 
particular, hereditary pancreatitis caused by germline mutations in the cationic trypsinogen gene [46] 
accounts for less than 1% of all chronic pancreatitis cases. Therefore, chronic pancreatitis does not 
constitute a main precursor of pancreatic cancer [9,42]. 
Despite this low incidence, both forms of chronic pancreatitis have provided substantial evidence 
for putative inflammatory mechanisms contributing to pancreatic cancer development and progression, 
including proinflammatory cytokines, nuclear factor-κB (NF-κB), cyclooxygenase-2 (COX-2), 
peroxisome proliferator-activated receptor-γ (PPARγ), nitric oxide (NO) synthesized by inducible NO 
synthase (iNOS), DNA damage caused by release of proteolytic enzymes and ROS, and somatic 
mutations in oncogenes (e.g., K-ras) and tumor suppressor genes (e.g., p53, p16, DPC4/Smad) [47-49]. 
Pancreatic cancer progression shares these molecular alterations, which are promising targets for early 
molecular diagnosis, treatment, and prevention of the disease [47-49]. 
Histopathologic findings of chronic pancreatitis include marked fibrosis, in which pancreatic 
stellate cells (PSCs) play a crucial role [50,51]. In the normal pancreas, quiescent PSCs produce 
vitamin A in the periacinar and interlobular space. In response to pancreatic inflammation, PSCs are 
activated and transformed to a myofibroblast-like phenotype; they proliferate, migrate and produce 
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extracellular matrix components (e.g., collagens, laminin, fibronectin), matrix metalloproteinases, and 
tissue inhibitors of matrix metalloproteinases. This phenotypic change is induced by inflammatory 
cytokines (e.g., tumor necrosis factor, interleukin-1, and interleukin-6), growth factors such as 
transforming growth factor (TGF)-β1, TGF-α, platelet-derived growth factor (PDGF), and fibroblast 
growth factor (FGF)-2; and ROS [52]. In addition to their roles in the pathogenesis of chronic 
pancreatitis and cancer, these factors also promote pancreatic cancer progression [50,51]. 
3.2. Cancer-Stromal Interaction and Tumor Microenvironment 
Chronic inflammation, desmoplastic stromal reaction, and neovascularization associated with 
pancreatic cancer combine to produce a distinct tissue microenvironment where cancer cell 
proliferation and invasion are facilitated by cancer-stromal interactions [53,54]. Activated PSCs are 
primarily responsible for the desmoplastic reaction and tumor angiogenesis in response to various 
growth factors such as TGF-β, FGF, HGF, and IGF-1. Results from in vitro and in vivo studies suggest 
that cancer cells recruit PSCs to tumors, where PSCs promote cancer cell proliferation and facilitate 
their invasion and metastasis, and that FGF and PDGF mediate these interactions between the two cell 
types (reviewed in [55]).  
Phenotypic changes also occur in cancer cells, as represented by epithelial-mesenchymal transition 
(EMT) at the interface between tumor and stroma, in which epithelial cells undergo morphologic 
changes characterized by a transition from epithelial to fibroblastic (mesenchymal cell) phenotypes. 
Most factors involved in pancreatic cancer-stromal interactions have the potential to induce EMT in 
cancer cells. This process involves loss of cell-to-cell adhesion and E-cadherin expression, actin 
cytoskeleton reorganization, and increased expression of mesenchymal molecules (e.g., vimentin, 
fibronectin, α-smooth muscle actin, N-cadherin). In this way, EMT facilitates the invasion and 
metastasis of cancer cells and renders them resistant to chemotherapy and radiation [56,57]. 
Accordingly, growth factors such as TGF-β and hepatocyte growth factor (HGF, or its receptor c-Met) 
that are involved in cancer-stromal interactions and EMT have been well studied in order to develop 
therapeutic strategies targeting these factors [53,54]. 
4. Targeting Molecular Pathways Deregulated in Pancreatic Cancer 
Most cases of pancreatic cancer are resistant to conventional chemotherapy and radiation 
therapy [5-7]; therefore, new strategies are needed to enhance the antitumor effects of gemcitabine, 
which is the standard chemotherapeutic agent used to treat pancreatic cancer [58]. These new classes 
of biology-based treatment modalities include molecular target-directed therapies. 
4.1. Deregulated Molecular Pathways Mediated by Receptor-Type Tyrosine Kinases 
Molecular studies have investigated the complex genetic mechanisms of cancer, which involve 
multidirectional signal transduction pathways [3,59,60]. As shown in Figure 2, the major signal 
transduction pathways in pancreatic cancer pathogenesis and progression are RAS/mitogen-activated 
protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR, and hedgehog pathways [3]. 
The receptor tyrosine kinase family and their ligands, which include epidermal growth factor (EGF) 
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receptor (EGFR), vascular endothelial growth factor (VEGF) receptor (VEGFR), and PDGF receptor 
(PDGFR), are targets of therapy because they are overexpressed in many tumor types, including 
pancreatic cancer [61].  
Figure 2. Critical molecular pathways leading to the development and progression of 
pancreatic cancer. Abbreviations: ARRB2, arrestin 2 ; COS2, kinesin-related protein 
Costal 2; DUSP6, dual specificity phosphatase 6; EGF, epidermal growth factor;  
EGFR, EGF receptor; GRK2, G protein-coupled receptor kinase-2; IRS, insulin receptor 
substrate 1; M, cell membrane; MAPK, mitogen-activated protein kinase; MAP2K, MAP 
kinase kinases; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol  
3-kinase; PTCH, patched; PTEN, phosphatase and tensin homolog deleted in chromosome 
10; Shh, sonic hedgehog; SMO, smoothened; SUFU, suppressor of fused; TSC, tuberous 
sclerosis complex; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 
The gray triangle in a box indicates a target for drug development. 
 
4.2. Pharmacologic Agents that Target Deregulated Kinases 
Currently available agents that target these factors include anti-EGFR antibodies (cetuximab, 
panitumumab), small molecule EGFR inhibitors (gefitinib, erlotinib), an anti-VEGF antibody 
(bevacizumab), and a small molecule VEGFR inhibitor (axitinib). A number of phase III clinical trials 
have tested kinase inhibitors as monotherapy or in combination therapy with gemcitabine for 
pancreatic cancer, but other than the combination of erlotinib and gemcitabine [62], these approaches
 
have produced few therapeutic benefits [63]. Characterization of new molecular targets is necessary in 
order to develop strategies that enhance the effect of gemcitabine and improve the survival rate. Recent 
studies have pursued potential kinases as targets for new anticancer agents [64] and evaluated agents 
targeting known kinases (e.g., EGFR, check-point kinase 1) to combine with gemcitabine in order to 
improve its antitumor effects [65]. 
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5. GSK3β, an Emerging Therapeutic Target in Cancer 
GSK3β has emerged as a critical factor that plays distinct pathologic roles in glucose intolerance, 
inflammation, and in various cancer types (e.g., pancreatic cancer). Here, we briefly review recent 
studies, including our own, that demonstrate the direct anticancer effects of GSK3β inhibition, alone or 
in combination with chemotherapy and radiation. 
5.1. Outline of GSK3β and its Involvement in Chronic Progressive Diseases 
GSK3β was first identified as a serine/threonine protein kinase that regulates glucose/glycogen 
metabolism under the control of insulin signaling. Unlike most protein kinases, GSK3β is active in 
normal cells, and its activity is controlled by subcellular localization, differential phosphorylation at 
serine 9 (S9) and tyrosine 216 (Y216) residues, and different binding partners. In addition to regulating 
its primary target, glycogen synthase, GSK3β is involved in other fundamental cellular pathways 
depending on its substrates and binding partners [66-68]. GSK3β is a potential therapeutic target for 
common chronic diseases including type 2 DM and Alzheimer’s disease, given the causative 
associations with glucose intolerance, neurodegenerative disorders, and inflammation [69-71].  
5.2. Pathologic Role of GSK3β in Various Cancer Types 
Under physiologic conditions, GSK3β phosphorylates several transcription factors (e.g., c-Jun,  
c-Myc), cell cycle regulators (e.g., cyclin D1), and proto-oncoproteins (e.g., β-catenin), thereby 
triggering their degradation via the ubiquitin-proteasome system. GSK3β is, therefore, hypothesized to 
inhibit tumor development by interfering with oncogenic signaling (e.g., Wnt, hedgehog) [72]. 
However, there is little evidence that links GSK3β inactivation or loss of GSK3β expression with 
tumor development. 
In the last five years, we demonstrated that deregulated expression, phosphorylation of S9 and 
Y216, and GSK3β activity are distinct features of gastrointestinal cancers including pancreatic cancers 
and glioblastoma, and that GSK3β sustains the survival and proliferation of these tumor cells. A 
pathologic role for GSK3β is supported by observations that inhibition of its activity reduced the 
survival and proliferation of different cancer cell types, predisposing them to apoptosis both in vitro 
and in tumor xenografts [73-76]. We also found that GSK3β inhibition in cancer cells was 
accompanied by restoration of p53 and Rb tumor suppressor pathways [75,76] and downregulation of 
human telomerase reverse transcriptase (hTERT), resulting in cell senescence [76]. This led us to 
propose GSK3β as a potential target for cancer treatment and to apply for domestic and international 
patents [77].  
Simultaneously and following our studies on the antitumor effects of GSK3β inhibition, similar 
observations from other laboratories were reported for various cancer types with underlying 
mechanisms that included regulation by GSK3β inhibition of several pathways mediated by p53, Rb, 
p27
Kip1
, cyclin-dependent kinase (CDK), cyclin D1, c-Myc, and NF-κB [78]. Although the putative 
role of GSK3β in cancer is still debated [79,80], the overall results indicate that aberrant expression 
and activity of GSK3β is likely to be a common and fundamental characteristic of a broad spectrum of 
cancers (Figure 3) [78].  
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Figure 3. Systemic and local effects of aberrant GSK3β on risk factors (glucose intolerance 
and chronic inflammation) and progression of pancreatic cancer. Molecular mechanisms 
leading to the pathways indicated by the dotted arrows are not well characterized. 
 
 
Based on the potential involvement of GSK3β in NF-κB-mediated cell survival [81,82], a number 
of studies demonstrated that GSK3β is involved in pancreatic cancer cell survival via the NF-κB 
pathway [83-85]. Few studies had focused on the role of GSK3β in the cellular response to 
chemotherapy until we reported that GSK3β inhibition sensitizes glioblastoma cells to 
chemotherapeutic agents (e.g., temozolomide, ACNU) and ionizing radiation [75]. However, a recent 
study failed to demonstrate that disrupting NF-κB activity by inhibiting GSK3β sensitizes PANC-1 
pancreatic cancer cells to gemcitabine [85]. We previously found that GSK3β inhibition did not affect 
endogenous NF-κB transcriptional activity in tumor cells established from pancreatic cancers and 
glioblastoma [75,76]. In a preliminary study, we found that a small-molecule GSK3β inhibitor 
increased pancreatic cancer cell sensitivity to gemcitabine in cell culture and tumor xenografts when 
its dose and treatment protocol were optimized, and have identified the molecular mechanisms 
underlying the increased sensitivity [86]. Our findings indicate that GSK3β inhibition combined with 
chemotherapy is a novel and promising strategy to sensitize pancreatic cancer cells to gemcitabine. 
5.3. Putative Antitumor Effects of GSK3β Inhibition via Modulation of Tumor Biology 
Increasing evidence suggests that GSK3β participates in a wide range of physiological processes 
that determine cell fate, including cell motility, energy metabolism, and transcriptional control 
(reviewed in [78]). In addition to the pathologic roles of GSK3β in cancer cell survival and 
proliferation [73-78,83-85] as discussed above, GSK3β may influence critical biological properties of 
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cancer cells, such as their dependence on glycolysis and invasive ability associated with EMT (Figure 3). 
Modulation of these biological properties by pharmacologic inhibition of GSK3β may sensitize 
pancreatic cancer cells to standard chemotherapy and radiation. Given the systemic pathology caused 
by aberrant GSK3β activity in glucose intolerance and chronic inflammation [71], GSK3β inhibition 
may decrease the risk of developing pancreatic cancer by improving these conditions. Accordingly, 
investigating the functions and pathologic roles of GSK3β should establish a firm molecular basis for 
future cancer treatments that target this kinase. 
6. Perspectives 
Here, we reviewed recent studies on the epidemiologic characteristics of pancreatic cancer and the 
molecular and biological mechanisms contributing to its development and progression, and highlight 
advances in alternatives to conventional treatments. Although molecular target-directed therapy is 
currently attracting considerable attention, especially for cancer refractory to standard chemotherapy 
and radiation, this therapy produces therapeutic effects that are still far from sufficient for most 
patients with advanced and recurrent pancreatic cancer. For many cancer patients, including those with 
pancreatic cancer, resistance to currently available therapeutics presents a major obstacle and is due to 
the aberrant metabolism of cancer cells, their microenvironment, their ability to invade and metastasize, 
and the acquisition of gene mutations. Multidisciplinary approaches directed to a more complete 
understanding of pancreatic cancer pathogenesis hold great promise in improving the outlook of  
this disease.  
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